JNMT
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME Activity
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cole, W. C.
Right arrow Articles by Bloodworth, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cole, W. C.
Right arrow Articles by Bloodworth, G.

Essential Role of Nuclear Medicine Technology in Tositumomab and 131I-Tositumomab Therapeutic Regimen for Non-Hodgkin's Lymphoma*

William C. Cole1, Jennifer Barrickman, CNMT2 and Glen Bloodworth, CNMT2

1 University of Colorado Health Sciences Center, Denver, Colorado; and 2 GlaxoSmithKline Oncology, Research Triangle Park, North Carolina


Figure 1
View larger version (24K):

[in a new window]
  		FIGURE 1.  Duration of response. (Reprinted with permission of (2).)

 

Figure 2
View larger version (22K):

[in a new window]
  		FIGURE 2.  Steps in tositumomab and 131I-tositumomab therapeutic regimen.

 

Figure 3
View larger version (92K):

[in a new window]
  		FIGURE 3.  Expected biodistribution showing blood-pool activity in heart and major vessels on first scan (A) decreasing in intensity on second scan (B) and third scan (C) for patient with NHL. Moderate uptake in liver and spleen on first scan progressively diminishes in intensity on second and third scans. Views are anterior.

 

Figure 4
View larger version (83K):

[in a new window]
  		FIGURE 4.  Expected biodistribution showing blood-pool activity in heart and major vessels on first scan (A) decreasing in intensity on second scan (B) and third scan (C) for patient with retroperitoneal adenopathy. Moderate uptake in liver and spleen on first scan progressively diminishes in intensity on second and third scans. Tumor uptake is seen as 2 focal areas of moderate uptake in upper to middle abdomen, best seen on second scan, corresponding to retroperitoneal adenopathy seen on CT scan. "Butterfly"-shaped uptake seen in neck on third scan represents thyroid uptake. Views are anterior.

 

Figure 5
View larger version (96K):

[in a new window]
  		FIGURE 5.  Expected biodistribution for patient with lymphomatous nodules. Multiple areas of various sizes, configurations, and intensities are seen in right upper chest wall laterally, epigastric region just to right of midline, lower right abdomen laterally, bilateral inguinal regions, and proximal right thigh on second scan (B). Some of these areas persist on third scan (C). These areas represent cutaneous lymphomatous nodules. Focal intense uptake is first seen in left upper abdomen on third scan, most likely representing activity in fundus of stomach. Views are anterior.

 

Figure 6
View larger version (72K):

[in a new window]
  		FIGURE 6.  Example of TBRT after dosimetric administration of tositumomab and 131I-tositumomab. Best-fit line for 2 assessment time points and 100% initial time point are shown.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE JOURNAL OF NUCLEAR MEDICINE JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
Copyright © 2006 by the Society of Nuclear Medicine Technologist Section.